Stockholm, Sweden – October 31, 2024 – This three-way collaboration marks a significant step towards expanding access to advanced breast cancer diagnostics and accelerating time to results for patients and treating physicians.
Capio St Göran’s Hospital is one of the largest breast cancer clinics in Sweden treating more than 600 breast cancer patients annually. With this new collaboration, Unilabs will use Stratipath Breast on a selected group of these patients, and thereby integrate AI-based precision diagnostics directly into the clinical workflow. Stratipath Breast leverages deep learning to analyse digital routine histological images for risk stratification, providing a rapid assessment of the risk of relapse for breast cancer patients.
“Stratipath Breast enables us to provide more patients with high-quality diagnostic insights faster than ever before,” says Eugenia Colón, senior consultant pathologist at Unilabs. “This collaboration with St Göran’s Hospital demonstrates our commitment to advancing cancer care by leveraging the latest in AI technology.”
Expanding access to precision diagnostics
Stratipath Breast is the first AI-powered solution of its kind compliant for clinical use. It analyses histopathological images of breast cancer to deliver prognostic information associated with a patient’s risk of relapse, providing critical insights to support physicians in making informed treatment decisions. Stratipath Breast has already been in clinical use for more than a year in several hospitals and hundreds of patients’ breast tumours have been analysed. These successful implementations are expected to bring enhanced diagnostic accuracy and efficiency. By incorporating Stratipath Breast into their diagnostic workflow, Unilabs and St Göran’s Hospital are paving the way for a larger group of breast cancer patients to gain access to precision diagnostics. This advanced AI-driven solution enables a broader range of patients to benefit from a reliable, data-driven assessment that can help guide treatment decisions.
Shortening the time to results
The most significant impact of this implementation is the significant reduction in the time required to deliver diagnostic results. Stratipath Breast produces a detailed risk stratification report within the hour, which will allow clinicians at St Göran’s Hospital to quickly have the information they need to make timely and informed decisions.
“Implementing Stratipath Breast at Unilabs and St. Göran’s Hospital represents a major leap forward in our mission to make precision medicine accessible to a broader patient population,” says Annica Jämten Ericsson, COO of Stratipath. “Unilabs has a strong track record of embracing innovations in cancer care, and we are thrilled about this close collaboration.”
By implementing Stratipath Breast, St Göran’s Hospital and Unilabs are advancing their shared mission of delivering high-quality, patient-centred care, ensuring that more breast cancer patients receive timely and enhanced diagnostics. The implementation and clinical assessment of Stratipath Breast is supported by Regional Cancer Centers Stockholm (RCC).
For more information, please visit www.stratipath.com or contact us at info@stratipath.com.
